BiotechTube
XtalPi

XtalPi

Cambridge, United States· Est.
en.xtalpi.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $461M

Overview

Founded in 2014 by MIT physicists, XtalPi has evolved from a pioneer in crystal structure prediction (CSP) into a comprehensive AI and automation platform for drug discovery. The company leverages a proprietary 'Hybrid AI + QM Discovery Engine' that combines quantum mechanics, machine learning, and robotic labs to design, predict, and synthesize novel drug candidates with high efficiency. With over 80 partners in pharma and biotech, a team of 1000+ employees, and a proven track record including contributions to Paxlovid's development, XtalPi is positioned as a key technology enabler in the rapidly growing AI-driven drug discovery sector.

AI / Machine Learning

Technology Platform

Hybrid AI + QM Discovery Engine integrating quantum physics-based computational modeling, machine learning, and robotic laboratory automation (Autonomous Lab Solution) for end-to-end drug discovery.

Funding History

3
Total raised:$461M
Series D$400M
Series C$46M
Series B$15M

Opportunities

The massive and growing market for AI in drug discovery, driven by pharma's need for greater R&D efficiency.
Expansion into new therapeutic modalities like peptides and potentially biologics.
The ability to monetize its software platforms as standalone SaaS products alongside integrated service offerings.

Risk Factors

Intense competition from other AI drug discovery platforms and in-house efforts by large pharma.
Dependency on partner R&D budgets and the risk of being viewed as a commodity service provider.
High operational and R&D costs required to maintain a technological edge across AI, quantum physics, and robotics.

Competitive Landscape

XtalPi operates in the highly competitive AI-driven drug discovery sector, competing with pure-play software companies (e.g., Schrödinger), AI-native biotechs (e.g., Recursion, Exscientia), and tech giants (e.g., Google's Isomorphic Labs). Its key differentiation is the deep integration of first-principles quantum mechanics with AI and its proprietary robotic lab infrastructure, creating a closed-loop 'phygital' platform that few rivals can match in scope.

More companies in AI / Machine Learning →More companies in United States →